Rate My Professor Suming Huang

Dr. Huang has authored over 140 publications, accumulating more than 4,400 citations and an h-index reflecting substantial influence in epigenetics and oncology. Key publications encompass 'HoxBlinc lncRNA reprograms CTCF-independent TADs to mediate HOXA cluster activation in leukemia' (Journal of Clinical Investigation, 2025), 'Long noncoding RNAs: emerging regulators of normal and malignant hematopoiesis' (Blood, 2021), 'Gene mutations linked to worse leukemia outcomes in Hispanic and Latino children' (2021), 'Researchers uncover genetic bridge to leukemia development' (2022), and 'AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy' (2020). He has received major funding, including a National Cancer Institute grant of $520,285 for exploring HOTTIP/β-catenin-HOXA9/PRMT1 interactions in AML. Dr. Huang contributes to graduate education as a dissertation advisor and committee member, and participates in international conferences like the SCBA International Symposium. His research advances therapeutic strategies for pediatric cancers through insights into epigenetic vulnerabilities.